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Background: Despite numerous studies a clear relationship between genotype and pulmonary phenotype has not been established within the group
pancreatic insufficient cystic fibrosis (CF) patients. We studied the relationship between class I and class II mutations and pulmonary function in
Swedish patients with known CFTR functional classification.
Methods: 170 CF patients with two class II mutations, 18 with two class I mutations and 78 with a combination of class I and II mutations were
included in the study. Spirometry was performed when patients were in an optimal clinical condition.
Results: Patients with two class I mutations had lower lung function (FEV1 and FVC) compared to the group with either a combination of class I
and II mutations or two class II mutations.
Conclusion: CF patients carrying two class I mutations risk developing more severe lung disease compared to patients with at least one class II
mutation.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; CFTR; Mutation class; Lung function1. Introduction
Cystic fibrosis (CF) is the most common life-shortening
autosomal recessive hereditary disease in Caucasians. The gene
cystic fibrosis transmembrane conductor regulator (CFTR) was
identified in 1989 [1] and as of April 2010 more than 1700
mutations have been identified [2]. Most of the mutations are
rare and occur in compound heterozygous CF patients.
CF is a complex disease with multi-organ involvement. The
correlation between genotype and disease severity varies
depending on the affected organ systems. For example, the
genetic penetrance of CFTR mutations is high in the sweat
glands and the male reproductive system, resulting in a high
content of salt in the sweat and congenital absence of bilateral☆ Data from this manuscript was presented at the North American Cystic
Fibrosis Conference, October 2005, Baltimore, Maryland, USA.
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mutations and pancreatic status, has led to a classification of
either mild or severe mutation depending on whether the
mutation results in pancreatic insufficiency or not [3]. The
phenotypic expression in the respiratory system varies greatly
and few correlations between genotype and pulmonary
phenotype have been established. One exception is that patients
with pancreatic insufficiency generally have more severe
pulmonary disease compared to patients with normal function
[4].
CFTR mutations have been grouped into different classes
based on their predicted functional consequences for the CFTR
protein [5–8]. Class I mutations affect the biosynthesis,
resulting in no CFTR protein at the apical membrane,
exemplified by the two Nordic mutations 3659delC and
394delTT. Class II mutations affect the protein maturation,
with abnormal processing and trafficking. This normally results
in no detectable CFTR protein at the apical membrane.
However the most common class II mutation, F508del, may
possess residual chloride channel activity. If this defectived by Elsevier B.V. All rights reserved.
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group of class III mutations [9,10]. The rescued F508del protein
is however a less potent chloride channel and as there is less
mutant CFTR protein at the apical membrane it could also
theoretically be classified as a class IV or V mutation. Class III
mutations affect the chloride channel regulation resulting in a
normal amount of non-functional CFTR protein at the apical
membrane. Class IV mutations affect the chloride conductance
resulting in a normal amount of CFTR protein with some
residual function at the apical membrane. Class V mutations
reduce the synthesis of CFTR protein, which gives a reduced
amount of functional CFTR protein at the apical membrane.
Class VI mutations affect the stability of CFTR protein,
resulting in a functional but unstable CFTR protein present at
the apical membrane [11]. Class I, II, III and VI mutations
usually result in pancreatic insufficiency, and are thus
considered severe mutations. However no severity grouping
has been performed within the class I – II – III – VI group.
Class IV and V mutations are habitually associated with a mild
disease and a normal pancreatic phenotype.
1.1. Aim of study
Our primary aim was to investigate if, in a cross sectional
study, two class Imutations had an implication on lung function in
CF compared with patients carrying two class II mutations or a
combination of class I and IImutations. Our secondary aimwas to
determine if chronic colonisation with Pseudomonas aeruginosa
differed between the patients with class I and II mutations.
2. Patients and methods
All 427 Swedish patients included in the study, “Differences
in prevalence and treatment of P. aeruginosa in Cystic Fibrosis
centres in Denmark, Norway and Sweden” [12], initiated by the
Scandinavian CF Study Consortium, were included in this
study. We initially intended to analyse the whole Scandinavian
CF population but there were only two patients homozygous for
class I mutations in Norway and no CF patients carried this
combination of mutations in Denmark. Furthermore the
treatment and segregation policies regarding P. aeruginosa
infections differ between the countries, whereas the caretaking
in the Swedish centres is more homogenous [12].
The standard care in Swedish centres includes inhalation
of salbutamol combined with a mucolytic followed by
chest physiotherapy. Most patients are on oral mucolytics,
N-acetylcystein or bromhexine or both. All centres use on
demand antibiotics therapy when the patients show signs of low
grade infection (for definition of low grade infection see below).
The policy of all centres is to give ten days of i.v. antibiotics to
patients with chronic P. aeruginosa infection when experiencing
an exacerbation. Most chronically colonised patients also are
treated with azitromycin continuously. Very few selected patients
(usually the ones on waiting list for lung transplantation) are
treated with long term inhaled antibiotics.
The Swedish patients were treated at one of the four Swedish
CF Centres; Gothenburg, Lund, Stockholm, and Uppsala. Thetwo most common class I mutations in Sweden, 3659delC and
394delTT, aremore frequent the further north you are, thus the CF
centre in Lund, serving the most southern part of Sweden, has
only one patient with two class I mutations, and Gothenburg only
three patients with this combination. On the other hand the
F508del mutation is more frequent in southern Sweden. Of the
427 Swedish patients included in the study 293 (146 men)
fulfilled the inclusion criteria; confirmedCF diagnosis, twoCFTR
mutations with known mutation classes, and ≥6 years old.
The CF diagnosis was based on positive sweat tests and
clinical features. The CFTR genes were analysed by established
molecular techniques [13–15] and grouped according to
functional classification first suggested by Tsui [5], later modified
byWelsh [6] and Zielenski [7]. Two patients had undergone liver
transplantation. Lung transplanted patients were excluded.
Lung function tests were performed with the patient in optimal
clinical condition, i.e. no sign of low grade infection. Signs of low
grade infection were defined as at least two of the following
symptoms; increased cough, increased sputum production and/or
change in appearance of sputum, temperature≥38 °C, absence of
weight gain or weight loss, new findings on chest examination
such as rales, and/or crackles and wheezing, decreased exercise
tolerance, decreased FEV1 (% of predicted) of N5% from
previous baseline value within the last month, or new findings
on chest X-ray [16]. The dynamic spirometry was performed at
each centre, according to the local routine, measuring forced
expiratory volume in one second (FEV1) and forced vital capacity
(FVC) in litres. Percentage of predicted values were calculated
using Solymar [17] and Quanjer [18] reference equations for
patients under 19 or ≥19 years, respectively.
Chronic P. aeruginosa colonisation was defined as ≥3
positive bacterial cultures and/or two or more crossed
immunoelectrophoresis (CIE) precipitating antibodies (precipi-
tins) against P. aeruginosa during the last 6 months [19].
Intermittent colonisation was defined as P. aeruginosa bacteria
grown from sputum at least once during life, but less than three
positive cultures and/or less than two CIE precipitins during
the last 6 months. Non colonised patients were determined by
P. aeruginosa never having being cultured and 0–1 precipitins
(=normal values). CIE against P. aeruginosa has in Danish
studies shown a high sensitivity and specificity for detecting
patients with chronic infection [19,20].
BMI was calculated as weight in kg/(height in m)2. For the
patients below 18 years of age BMI z-score was calculated
using the references published by Rolland-Cachera [21]. To
make a comparison of BMI between children and adults the
patients were classified in two groups; normal (BMI z-score b2
and BMI≤25 respectively), and overweight. There were too
few underweight patients to analyse as a separate group, e.g.
one child and four adults [22].3. Statistics
Descriptive statistics were presented with mean and standard
deviation (STD) for continuous variables and absolute and
relative frequencies for categorical variables.
Table 1
The different CFTR mutations according to functional class.
Class I Class II Class III Class IV Class V
1717-1 G-NA F508del G551D 297 C-NA 2789+5 G-NA
3659delC S945L R560T R117C 3849+10 kb CNT
394delTT R347P A455E
R553X T 3381 3849+10 kb C-T
621+1 G-NT
E60X
G542X
W79R
W1282X
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covariance (ANCOVA), partly with only class/class in the
model and partly adjusted for diabetes, chronic colonisation
with P. aeruginos, age at diagnosis, age, sex and BMI group.
The assumptions, normality and homoskedasticity, were
investigated, together with potential outliers, by means of
plots and the Kolmogorov–Smirnov test and no violations were
detected.
All analyses were performed in SAS v 9.2 (SAS Institute
Inc., Cary, NC, USA). All tests are two-sided and performed at
the 5% significance level with no adjustments for multiple
comparisons.
4. Ethics
The Regional Ethics Committees of the Universities of
Gothenburg, Lund, Uppsala and of Karolinska Institutet
approved the study and informed written consent was obtained
from all patients.
5. Results
The CFTR mutations are shown in Table 1. In Table 2
mutations and the combinations of associated classes are
depicted.
Fifteen males and three females were carrying two class I
mutations. Among the ones with two class II mutations there
was no male preponderance. The mean age for all patients was
20 years. BMI was similar in all groups except in the class II/IVTable 2
The different CFTR mutations combinations of class I and class II mutations.
Class I/class I Class I/class II
1717-1 G-NA/1717-1 G-NA n=1 3659delC/S945L
3659delC/3659delC n=5 3659delC/F508del
3659delC/394delTT n=7 394delTT/F508del
394delTT/394delTT n=4 621+1 G-NT/F508
R553X/E60X n=1 E60X/F508del
G542X/F508del
R553X/F508del
W79R/F508del
W1282X/F508del
1717-1 G-NA/F508
Total 18
The other class combinations are not shown. (Class I/III=1, class I/IV=3, class II/Igroup where it was slightly higher. Patients b18 years made up
approximately 50% of all the patients except in the class I/I
group where they were 33%.
The mean FVC for all patients was within the normal range,
Table 3. The overall p-value of effect in between groups
regarding FVC was not significant, however, the group with
two class I mutations had a 9.5% lower FVC compared to the
patients carrying two class II mutations and 11.3% lower than
the compound class I/II mutations (p=0.0473)/(p=0.0249).
FEV1 was 13.1% lower in the class I/I group compared to the
class II/II group (p=0.0130) and 13.4% lower than the class I/II
group (p=0.0164). There was no difference between class I/II
and class II/II regarding either FEV1 or FVC, Table 4.
There were no differences in the degree of chronic
P. aeruginosa colonisation between any of the groups, Table 3.
When analysing data from Stockholm and Uppsala CF centres,
thus excluding the patients from southern Sweden and in
consequence the regional differences in the frequency of CFTR
mutations, the patients with two class I mutations (n=14) had,
with the univariate analysis, a 14% lower FEV1 (p=0.046) than
patients with two class II mutations (n=74). The class I/I group
also had lower lung function than the class I/II group (n=39);
FEV1 15% lower (p=0.0352) and FVC 14% lower (p=0.0286).
However when adjusting for diabetes, chronic colonisation
with P. aeruginosa, age at diagnosis, age, sex and BMI group
the lower FEV1 for class I/I was only significant in comparison
with class I/II (in comparison with class II/II p=0.0598), Table 5.
6. Discussion
Theoretically class I mutations are more severe than class II
mutations as they result in an absence of CFTR protein at the
apical membrane. In line with this our data indicate that class I
mutations result in a more severe lung disease than class II
mutations, with mean FEV1 13% lower in the class I/I mutation
group than in the class II/II group. An association between
different severe genotypes and CF pulmonary phenotype have,
hitherto only been reported in a recently published study by
Cleveland et al. who suggested that class I allele mutations were
associated with a faster decline in pulmonary status, lung
function and pulmonary X-ray scoring, than class II or III
mutations [23]. Corey et al. showed in a longitudinal study thatClass II/class II
n=1 F508del/F508del n=165
n=23 F508del/S945L n=5
n=38
del n=6
n=4
n=1
n=2
n=1
n=1
del n=1
78 170
II=3, class II/IV=17, class II/V=4, class III/V=1 patient).
Table 3
Combinations of mutation classes and patient characteristics.
Mutation class I/I I/II II/II II/IV
Total (n) 18 78 170 18
Males/females (n) 15/3 37/41 86/84 6/12
Age years ⁎ 22±12 19±10 19±9 22±11
Age males years ⁎ 21±12 19±10 20 ±10 20±6
Age females years ⁎ 29±13 19±9 18±9 23±13
Age males at diagnosis years ⁎ 2.2±4.4 2.1±2.5 1.9±3.3 7.4±7.1
Age females at diagnosis years ⁎ 0.6±0.7 1.5±2.5 1.6±3.1 12.1±14.4
FEV1% of predicted ⁎ 66±26 81±25 81±24 93±13
FVC% of predicted ⁎ 84±19 95±19 94±21 100±16
BMI (≥18 year) ⁎ 21±2.7 22±2.5 22±2.8 24±2.8
(n=10) (n=38) (n=80) (n=12)
BMI z-score (b18 year) ⁎ 0.5±1.3 0.4±1.1 0.3±1.1 0.7±0.6
(n=8) (n=40) (n=90) (n=6)
Under- and normal weight/overweight (n/n) 15/3 69/9 155/15 15/3
Chronic P. aeruginosa colonisation n=9 (50%) n=37 (47%) n=83 (49%) n=3 (17%)
Chronic B. cepacia colonisation n=1 (5%) n=1 (1%) n=5 (3%) 0
Diabetes mellitus n=2 (11%) n=14 (18%) n=27 (16%) 0
⁎ Values presented as mean±S.D.
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pancreatic insufficiency, mainly class II mutations, compared to
CF patients with normal pancreatic function [4].
Similarly, in a prospective study with adult CF patients, de
Gracia et al. showed that class I or II mutations on both
chromosomes were associated with lower mean baseline FVC
and FEV1 (predicted values) and a more rapid decline of lung
function than patients with at least one class III, IV or V
mutations [24].
However, in a study based on the Cystic Fibrosis Foundation
Registry Lai et al. did not find an increased risk of poor lung
function, defined as FEV1b70% in patients having two severe
genotypes other than F508del or patients with at least one allele
with a class IV or V mutation compared to patients homozygous
for F508del [25].
The combination of two class I mutations seems to be rare,
de Garcia and Cleveland had only three and five patients
respectively in their studies. The frequency of a class I mutation
on one allele ranged between 0 and 9% in the US based on dataTable 4
FEV1 and FVC analysed with and without adjustments for cofactors.
FEV1
Univariable
Mutation class/class Estimate 95% confidence interval p
0
I/I vs I/II −15.4991 −28.0, −3.0 0
I/I vs II/II −15.2963 −27.1, −3.4 0
I/II vs II/II 0.2028 −6.4, 6.8 0
FVC
0
I/I vs I/II −11.5311 −21.9, 1.1 0
I/I vs II/II −9.7144 −19.6, 0.1 0
I/II vs II/II 1.8166 −3.6, 7.3 0
⁎ Adjusted for diabetes, colonisation with P. aeruginosa, age at diagnosis, age, se
⁎⁎ The overall p-value of effect in between groups.from the US Cystic Fibrosis Foundation National Registry [26].
The study by Koch et al. [25] based on the European
Epidemiologic Registry of Cystic Fibrosis (ERCF) is so far
the only study that has presented data with a separate analysis of
lung function of patients with class I/I mutations compared to
class II/II patients. This study presented pooled data from all
European countries participating in the registry. Even in this
large database with 11,749 patients there were only 44 patients
with the class I/I combination. Though the difference was not
statistically significant the mean FEV1 was 33.7% for class I/I
and 52.7% for class II/II in the adult population. In our study we
had 18 patients. Swedish CF patients have the benefit of a well
functioning health care system with the same treatment tradition
all over the country. The analysis of patients only from Uppsala
and Stockholm CF centres, that see patients from the same
regions, likewise shows similar differences in lung function
between class I/I and both class I/II and II/II patients. The
significance is however not verified (p=0.0598) regarding the
difference in FEV1 between class I/I and II/II after adjustmentMultivariable ⁎
-value Estimate 95% confidence interval p-value
.037 ⁎⁎ 0.040 ⁎⁎
.0155 −13.3898 −24.3, −2.5 0.0164
.0118 −13.144 −23.5, −2.8 0.0130
.9515 0.2453 −5.4, 5.8 0.9313
.093 ⁎⁎ 0.080 ⁎⁎
.0298 −11.3033 −21.2, 1.4 0.0249
.0533 −9.4588 −18.8, −0.1 0.0473
.5111 −1.8445 −3.2, 7.0 0.4730
x and BMI (2 groups).
Table 5
FEV1 and FVC from Stockholm and Uppsala CF centres analysed with and without adjustments for cofactors. ⁎ Adjusted for diabetes, colonisation with
P. aeruginosa, age at diagnosis, age, sex and BMI (2 groups). ⁎⁎ The overall p-value of effect in between groups.
FEV1
Univariable Multivariable⁎
Mutation class/class Estimate 95% confidence interval p-value Estimate 95% confidence interval p-value
0.093⁎⁎ 0.120⁎⁎
I/I vs I/II −15.8431 −30.6, −1.1 0.0352 −13.7777 −27.2, −0.3 0.0449
I/I vs II/II −14.0138 −27.8, −0.2 0.0463 −12.1316 −24.8, −0.5 0.0598
I/II vs II/II 1.8293 −7.5, 11.2 0.6994 1.6461 −6.6, 9.9 0.6930
FVC
0.090⁎⁎⁎ 0.080⁎⁎
I/I vs I/II −14.3519 −27.2, −1.5 0.0286 −14.2850 −26.7, −1.8 0.0248
I/I vs II/II −10.6767 −22.7, 1.3 0.0807 −10.7118 −22.4, 1.0 0.0720
I/II vs II/II 3.6752 −4.5, 11.8 0.3737 3.5731 −4.0, 11.2 0.3546
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age, sex and BMI (2 groups), probably due to smaller numbers
with only 14 class I/I patients including two females.
The differences in pulmonary function thus do not reflect
different treatment policies enabling differences in phenotypes
to be seen. Furthermore in the study protocol all patients were
evaluated in an optimal clinical condition with no ongoing
exacerbation in order to standardise the investigation as much as
possible. The nutritional status reflected by BMI did not have an
impact on the pulmonary function in our study as the average
and median BMI was the same in the three groups with severe
mutations. Neither did chronic infection with P.aeruginosa
affect the outcome of the study. It seems unlikely that the
socioeconomic status of the patients should reflect on disease
severity on account of the Swedish social welfare system that
maximises the costs for medicines as well as health care.
Furthermore families with CF children can if needed get
additional economic benefits as well as extra resources both at
home, in kindergarten or at school.
Several studies have shown that the CFTR protein from
patients with the F508del mutation, a class II mutation, can be
detected in the cell membrane of epithelial cells [9,10]. Its
function can be influenced by certain drugs such as sodium-4-
phenylbutyrate (28, 29). It is possible that the residual function
of the defective CFTR protein can result in the better lung
function seen in the class II group compared to the group with
only class I mutations. Patients homozygous for the F508del
mutation have a wide spectrum of phenotypic variations. One
might speculate that modifier genes such as TGFβ1 codon 10
CC that acts as an adverse modifier of lung disease have a larger
impact on class I mutations [27,28]. Another possibility is that
environmental aspects such as smoking in combination with
modifier genes or by themselves may contribute to the
variability of the pulmonary phenotype. However, almost no
Swedish CF children are subjected to passive smoking and only
a few adult CF patients smoke arguing against this hypothesis.
Our study was limited by being cross sectional with only one
single lung function measurement. The age of onset of
P. aeruginosa was not known but in the year following the
study one patient (5%) in the class I/I group, three patients(3,9%) in the class I/II group, and eight patients (4,8%) in the
class II/II group became colonised with P. aeruginosa. On the
other hand the study was based on data from all centres in one
country with homogenous treatment for cystic fibrosis. The
number of patients with two class I mutations was low reflecting
their rarity. Despite the small number the differences were
statistical significant. Our study is in agreement with the
longitudinal findings by Cleveland et al. We believe that more
extensive functional classification of the CFTR mutations,
besides being severe or not, can be a helpful tool for clinicians
in determining the individual treatment for each CF patient.
Patients with two class I mutations may benefit from frequent
clinical checkups and more intensified treatment.
In conclusion in this cross sectional study, with the inherent
limitations that follows, we found that CF patients carrying two
class I mutations had lower lung function than patients with two
class II mutations and possibly when carrying a combination of
class I and II mutations. The degree of chronic colonisation with
P aeruginosa did not differ between the patients with class I and
II mutations or a combination of the two.
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